2014 Competition FDA Side effects 
Pharmaceutical Technology
NOVEMBER 30, 2022
In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects.
Pharmaceutical Technology
NOVEMBER 30, 2022
In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects.
Expert insights. Personalized for you.
105 
Let's personalize your content